Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis.
Baek
William S
WS
Bashey
Asad
A
Sheean
Geoffrey L
GL
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000201:enzymology; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis; D011950:Receptors, Cholinergic / Q000032:analysis; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D011950:Receptors, Cholinergic; D000069283:Rituximab; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases